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Introduction: Obesity became a major public health problem as a result of its increasing prevalence
worldwide. Paraoxonase-1 (PON1) is an esterase able to protect membranes and lipoproteins from
oxidative modifications. At the PON1 gene, several polymorphisms in the promoter and coding regions
have been identified. The aims of this study were i) to assess PON1 L55M and Q192R polymorphisms
as a risk factor for obesity in women; ii) to compare PON1 activity according to the expression of
each allele in L55M and Q192R polymorphisms; iii) to compare PON1 activity between obese and
normal-weight women.
Materials and methods: We studied 75 healthy (35.9G8.2 years) and 81 obese women (34.3G8.2
years). Inclusion criteria for obese subjects were body mass index R30 kg/m2 and absence of
inflammatory/neoplasic conditions or kidney/hepatic dysfunction. The two PON1 polymorphisms
were assessed by real-time PCR with TaqMan probes. PON1 enzymatic activity was assessed by
spectrophotometric methods, using paraoxon as a substrate.
Results: No significant differences were found for PON1 activity between normal and obese women.
Nevertheless, PON1 activity was greater (P!0.01) for the RR genotype (in Q192R polymorphism) and
for the LL genotype (in L55M polymorphism). The frequency of allele R of Q192R polymorphism was
significantly higher in obese women (P!0.05) and was associated with an increased risk of obesity
(odds ratioZ2.0 – 95% confidence interval (1.04; 3.87)).
Conclusion: L55M and Q192R polymorphisms influence PON1 activity. The allele R of the Q192R
polymorphism is associated with an increased risk for development of obesity among Portuguese
Caucasian premenopausal women.
European Journal of Endocrinology 164 213–218Introduction
Serum paraoxonase-1 (PON1, E.C.3.1.8.1) is a glycosy-
lated protein of 355 amino acids, with a molecular mass
of 43–47 kDa. It is synthesized by the liver and secreted
into the blood, where it circulates in association with
high-density lipoprotein cholesterol (HDLc) (1, 2).
PON1 is a calcium-dependent esterase known for
its ability to hydrolyze active metabolites of several
organophosphates (3, 4). Its primary physiological role
is the protection of low-density lipoprotein cholesterol
(LDLc) and HDLc from oxidative modifications
through enzymatic hydroxylation of oxidized phospho-
lipids (1, 4–6).
The enzymatic activity of PON1 varies widely among
healthy humans, and it has been suggested that subjects
with low PON1 activity may have a greater risk of
developing diseases in which oxidative damage and lipid
peroxidation are involved (2, 3, 7). Several studies have
demonstrated that the antioxidant activity of PON1ndocrinologyprevents oxidative stress mechanisms involved in
pathophysiological processes associated with athero-
sclerosis and diabetes mellitus, among other common
pathologies (8–11).
PON1 activity is modulated by environmental
compounds and lifestyle, but also by genetic polymorphisms
(7, 12). Human PON1 gene is coded on chromosome
7q21.3–22.1, and several polymorphisms have been
identified on its promoter and coding regions. Two
polymorphisms in the coding region of PON1 gene have
been identified and widely studied: non-synonymous amino
acid substitution Gln192/Arg (Q192R) and Leu55/Met
(L55M) (12, 13). The presence of each of these polymorph-
isms has shown to lead to different PON1 phenotype.
The presence of L55M (rs854560) has been associ-
ated with changes in the concentration of the enzyme
but small effects on its activity. On the other hand, the
polymorphism Q192R (rs662) leads to different PON1
enzymatic activity behavior dependent of the isoenzyme
that is present (4). These polymorphism-dependentDOI: 10.1530/EJE-10-0825
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to several pathological states such as diabetes mellitus
(14, 15), coronary disease (16, 17), and stroke (18, 19).
Obesity is a known risk factor for type 2 diabetes,
dyslipidemia, hypertension, and atherosclerosis. Several
studies have demonstrated an increase in oxidative
stress in obese subjects, namely with a significantly
higher susceptibility to lipid peroxidation (20). This
pathophysiological mechanism has been implicated in
the development of several comorbidities (21, 22).
Although PON1 expression has been associated with
an obesity-related phenotype (23), less is known about
the importance of this enzyme in the predisposition for the
development of obesity. To clarify this relationship, we have
studied the interaction between body mass index (BMI),
PON1 activity, and Q192R and L55M polymorphisms.
Studying a population of obese and normal-weight
Portuguese Caucasian premenopausal women, we
intended to assess PON1 L55M and Q192R polymorphisms
as a risk factor for obesity. Secondarily, we compared PON1
activity according to the expression of each allele (in both
polymorphisms) and between the two groups of women.Methods
Subjects
The obese group consisted of 81 obese Caucasian
premenopausal women, who attended the obesity out-
patient clinic at the Curry Cabral Hospital (Lisbon,
Portugal). Their age ranged from 18 to 50 years old, and
their BMI wasR30 kg/m2. All of them exhibited a!10%
variation in their body weight in the previous year.
The control group consisted of 75 healthy Caucasian
premenopausal women, who either attended a routine
health check or belonged to the health care staff of
Curry Cabral Hospital. Their age ranged from 18 to 50
years old, BMI from 18.5 to 24.9 kg/m2, and exhibiting
!10% variation on their body weight in the previous year.
Although all women, obese and controls, presented in
a fertile status, no one was pregnant or had been
pregnant in the preceding 12 months. We considered
only women without previous diagnosis of any acute/
chronic conditions (except obesity for the obese group).Table 1 Technical characterization of the primers and p
polymorphisms.
Sequence
Probes
192-Q 5 0-TCTCCCAGGATTGTAAGTAGG
192-R 5 0-TCTCCCAGGATCGTAAGTAGG
55-M 5 0-CGCGATCGGCTCTGAAGACAT
55-L 5 0-CGCGATCGGCTCTGAAGACTT
Primers
Forward 5 0-GAGCACTTTTATGGCACAAA-3
Reverse 5 0-TAGTAGACAACATACGACCAC
Forward 5 0-GTGAGGTGTGATAAAGAAATG
Reverse 5 0-AAAGAAAACACTCACAGAGC-3
www.eje-online.orgNo woman was on any pharmacological regimen,
except for oral contraceptives.
The study was conducted following the approval of
the institutional scientific and ethical boards, and an
informed consent was obtained from all participants.
Clinical evaluation
Each woman was anthropometrically characterized in
terms of BMI, waist circumference, waist:hip ratio, and
total body fat mass assessed by bioelectrical impedance
(Tanita TBF-300A, Tanita Europe B.V., Hoofddorp,
The Netherlands).
Sample collection
A fasting venous blood was collected from patients and
controls. Serum samples were obtained by low-speed
centrifugation and stored atK80 8C in an ultra-freezer,
and thawed just before each assay. For genetic analysis,
total blood was collected and stored at K20 8C.
Assessment of PON1 activity
PON1 activity assay used paraoxon (O,O-diethyl-
p-nitrophenylphosphate; Sigma–Aldrich) as a substrate,
following the rate of generation of p-nitrophenol (24).
Spontaneous paraoxon hydrolysis was subtracted.
PON1 activity was initiated by adding serum samples
to a reactive mixture containing 100 mM Tris–HCl
buffer (pH 8.0), 2 mM CaCl2, and 2 mM paraoxon. The
reaction was followed at 412 nm at 25 8C, with the use
of Heliosb u.v.–Vis v2.04 spectrophotometer. Enzyme
activity was calculated with a molar extinction
coefficient of 18 290/M per cm.
Analysis of L55M and Q192R polymorphisms
Genomic DNA was isolated from white blood cells by
phenol extraction. Genotyping was done through real-
time PCR with TaqMan probes, using iCycler iQ
Multicolor Real-Time PCR Detection System (Bio-Rad).
The design of the primers and probes (Table 1) was
done using the software Beacon Designer (Primerrobes for real-time PCR genotyping for paraoxonase-1
Fluorophore
GGT-3 0 FAM
GGT-30 TET
GGAGATACTGGATCGCG-30 TET
GGAGATACTGGATCGCG-30 FAM
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probes were acquired to Thermo Company (Whatman
BioScience, Newton, MA, USA).
For the study of both polymorphisms, we used
TaqMan Universal PCR Master Mix (Applied Biosys-
tems) with primers forward and reverse (300 nM) and
probes FAM and TET (250 and 150 nM respectively).
Amplification steps were 95 8C for 10 min, followed by
50 cycles at 92 8C for 15 s and 60 8C for 1 min.0
50
QQ QR RR
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Figure 1 Serum PON1 activity in control and study populations
according to the presence of different genotypes of the Q192R
polymorphism (P!0.01 with respect to the other two genotypes, for
the same population).Statistical analysis
Comparisons between the groups were made by Student’s
t-test. Odds ratio (OR) analysis was performed using
binary logistic regression adjusted for age. Interaction
between the polymorphisms and PON1 activity was
evaluated by ANOVA test. PON1 allelic polymorphisms
and genotypic distributions were analyzed by c2 test.
All determinations were performed using SPSS
software, version 16.0 (Somers, NY, USA).Results
The characteristics of the obese and control groups are
depicted in Table 2. The groups were well matched for
age but, as expected, were significantly different
concerning all the anthropometric parameters.
No significant difference in PON1 activity was
observed between control and study populations. A
significant correlation between PON1 activity and BMI
was presented in the obese group (PZ0.017; rZ0.84),
but not in the control one. Nevertheless, no correlations
of PON1 activity were observed with waist circumfer-
ence, waist:hip ratio, and total body fat mass (PO0.05).Table 2 Characterization of the obese and control groups included
in the study. Values are represented as meanGS.D.
Control
group
Study
group P value
n 75 81
Age (years) 35.9G8.2 34.3G8.2 0.23
BMI (kg/m2) 21.5G1.8 43.1G8.5 !0.001
Waist circumference (cm) 71.6G5.7 117.8G15.7 !0.001
Waist/hip ratio 0.74G0.05 0.88G0.07 !0.001
Fat mass (%) 25.1G4.5 47.4G5.3 !0.001
Systolic blood pressure
(mmHg)
108.7G13.6 124.3G17.5 !0.001
Diastolic blood pressure
(mmHg)
69.4G9.8 79.9G11.2 !0.001
Glycemia (mg/dl) 83.0G6.8 90.7G21.9 !0.001
HbAlc (%) 5.3G0.3 5.7G0.9 0.002
Triglycerides (mg/dl) 77.8G27.8 123.0G80.9 !0.001
Total cholesterol (mg/dl) 173.0G28.8 184.9G33.3 0.017
HDL-cholesterol (mg/dl) 67.6G14.6 51.2G11.7 !0.001
LDL-cholesterol (mg/dl) 108.0G26.8 118.7G27.8 0.014
High-sensitivity C-reactive
protein (mg/dl)
0.23G0.3 0.95G0.82 !0.001
Women on oral
contraceptives (%)
42.7% 45.7% 0.751The two polymorphisms are in linkage disequilibrium
(P!0.001). There is statistical linkage and physical
linkage, as they are in the same chromosome.
When we analyzed the activity of PON1, according to
the polymorphisms L55M and Q192R of PON1 gene,
there were significant differences in enzymatic activity
between genotypes. For the Q192R polymorphism
(Fig. 1), we found that the PON1 activity was
significantly higher in the presence of the genotype
RR and minor for QQ, with QR heterozygotes showing
an intermediate activity (P!0.01). For polymorphism
L55M (Fig. 2), a similar profile was verified: higher
PON1 activity for genotype LL, lower PON1 activity for
MM genotype, and intermediate PON1 activity for the
heterozygotes ML (P!0.01).
The polymorphism Q192R was in accordance with
the Hardy–Weinberg equilibrium in both groups. The
L55M polymorphism was in accordance with the
Hardy–Weinberg equilibrium in the obese group, but
not in the control one, where it presented a higher
prevalence of LL homozygotes (P!0.05; Table 3).
Nevertheless, when we analyzed the differences between
the allelic and genotypic distribution of the L55M
polymorphism, no significant dissimilarity was observed
(Table 3). Conversely, the polymorphism Q192R showed
significant differences in allelic and genotypic distri-
butions between the control and obese populations
(P!0.05), with an increased frequency of the R allele
in the obese group (Table 3).
OR analysis was performed for both Q192R and
L55M PON1 polymorphisms (Table 4). For the L55M
polymorphism, no significant influence was shown in
obesity (PO0.05), neither in genotypic nor in the allelic
form. The genotypic expression of the Q192R poly-
morphism did not represent a significant risk for the
development of obesity (Table 4). Nevertheless, the
presence of the R allele (QRCRR) represented a twofoldwww.eje-online.org
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Figure 2 Serum PON1 activity in control and study populations
according to the presence of different genotypes of the L55M
polymorphism (P!0.01 for MM genotype with respect to the other
two genotypes, for the same population).
Table 4 Odds ratio analysis for the studied PON1 polymorphisms.
Polymorphisms Odds ratioa (95% CI) P value
Q192R
QQ 1 –
QR 1.9 (0.95–1.80) 0.069
RR 2.5 (0.86–7.06) 0.091
QQ 1 –
QRCRR 2.0 (1.04–3.87) 0.036
L55M
MM 1 –
ML 2.2 (0.89–5.64) 0.085
LL 1.4 (0.55–3.49) 0.483
MM 1 –
MLCLL 1.8 (0.76–4.14) 0.186
aOdds ratio was calculated using binary logistic regression adjusted for age.
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risk for obesity.
No synergetic effect was observed in PON1 enzymatic
activity or in obesity risk when we combined the two
polymorphisms of PON1 gene.Discussion
In Portugal, the prevalence of overweight and obesity
has increased throughout the last decade, increasing to
more than half of the adult population (25), in
accordance with obesity epidemics worldwide. Many of
the metabolic pathways and interactions related to the
genesis of obesity are still unknown. That makes this
disease one of the major challenges of the 21st century
both in the clinical and in the investigational fields.
PON1 is an antioxidant enzyme that has been related
to several pathophysiological conditions, mainly
diseases associated with oxidative stress unbalanced
status. Two main common polymorphisms in theTable 3 Allelic and genotypic distributions of Q192R and L55M
polymorphisms for the participant populationsa.
Obese
population
Control
population P value
Q192R
QQ 27 (33.3%) 37 (50%) 0.038
QR 40 (49.4%) 30 (40.5%)
RR 14 (17.3%) 7 (9.5%)
Q 94 (0.58) 104 (0.703) 0.033
R 68 (0.42) 44 (0.297)
L55M
MM 11 (13.6%) 16 (21.6%) 0.828
ML 39 (48.1%) 26 (35.2%)
LL 31 (38.3%) 32 (43.2%)
M 61 (0.38) 58 (0.39) 0.809
L 101 (0.62) 90 (0.61)
aValues represent the number of cases (frequency).
www.eje-online.orgcoding region of the PON1 gene have been identified,
Q192R and L55M. They have been recognized by some
authors as genetic susceptibility factors for the develop-
ment of some diseases (13, 26).
In this study, no significant difference in PON1
activity was observed between obese and normal-weight
women. So, PON1 activity seems to have no direct
influence on the development of obesity. These results
could be due to the fact that PON1 activity is modulated
by several different factors (7), leading to a wide
variability in PON1 activity among individuals.
However, it was possible to determine a correlation
between PON1 activity and BMI, as already reported by
other authors (25).
When we analyzed the PON1 activity according to
the L55M and Q192R polymorphisms, it was possible
to verify that the LL and RR genotypes respectively lead
to a significant increase in the enzymatic activity of
PON1 in control and obese populations. Previous
studies have reported similar results in type 2 diabetes
mellitus (14) and cardiovascular diseases (27). This
behavior may be due to structural change promoted by
the polymorphism or changes in affinities to the
substrate of each isoenzyme (28).
It was possible to observe that the L55M poly-
morphism showed a deviation on the genotypic
distribution, which led to an increased number of
homozygote LL in the control population. However,
these findings were inconclusive because L55M poly-
morphism was not found as a predictive risk factor for
obesity. Further studies should be carried out to
determine the importance of the LL genotype in obesity.
For the Q192R polymorphism, there was a preva-
lence of the R allele in the obese population. Through
OR analysis, we could demonstrate that this allele was
actually a risk factor for obesity per se which lead to a
twofold increase risk for the development of obesity
in women.
It seems contradictory that higher PON1 activity is
associated with a higher risk of obesity. Nevertheless,
recent studies have shown that obesity is characterized
by a reduced redox state in adipose tissue, which would
Q192R paraoxonase-1 as a risk factor for obesity 217EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164promote a deleterious pro-adipogenic process (29). This
might indicate that if an elevated PON1 activity is
present, it means that it is actually a higher redox state
in the body. In this setting, adipogenic process would be
activated and obesity would be promoted.
The major contribution of this study is that we
demonstrate a direct influence of Q192R PON1
polymorphism as a risk factor for obesity.Declaration of interest
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